The Committee adopted the HAUG report on the Regulation relating to fees payable to the European Agency for the Evaluation of Medicinal Products. Through these amendments the Committee called on the Agency to indicate in its annual statement the estimates concerning the fees for the following financial year and to do this separately from the estimation of overall expenditure and the possible contribution by the Community. It stressed that fees constituted the Community's resources and were used to fund the Agency, with any surplus being assigned to the EU budget. Finally, the Committee took the view that a possible modification of the fees system should be based on Article 189B.
�